23andme Holding Co Quick Ratio (ME) starting from the first quarter 2025 to first quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
23andme Holding Co  (ME)

23andme Holding Co's Quick Ratio

ME's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2025, Quick Ratio fell to 0.36 below 23andme Holding Co average.

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Quick Ratio than 23andme Holding Co in first quarter 2025. While Quick Ratio total ranking has improved so far during the Q1 2025 to 542, from total ranking in the fourth quarter 2025 at 2073.

Explain Quick Ratio?
How much Cash & cash equivalents ME´s has?
What are ME´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ME Quick Ratio (Jun 30 2025)
Q1		 (Mar 31 2025)
Q4		 (Dec 31 2024)
Q3		 (Sep 30 2024)
Q2		 (Jun 30 2024)
Q1
Y / Y Current Liabilities Change -27.14 % -33.72 % 6.38 % 50.42 % 28.55 %
Y / Y Cash & cash equivalent Change -76.57 % -82.33 % -67.27 % -50.62 % -45.93 %
Quick Ratio MRQ 0.36 0.53 0.52 0.83 1.11
ME's Total Ranking # 542 # 2073 # 282 # 1561 # 739
Seq. Current Liabilities Change 53.2 % -52.59 % 0.33 % -0.02 % 39.34 %
Seq. Cash & cash equivalent Change 4.13 % -51.8 % -37.32 % -25.52 % -21.49 %



Quick Ratio first quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 35
Healthcare Sector # 91
Overall Market # 542


Quick Ratio Statistics
High Average Low
6.28 2.36 0
(Jun 30 2021)   (Mar 31 2021)




Financial Statements
23andme Holding Co's Current Liabilities $ 111 Millions Visit ME's Balance sheet
23andme Holding Co's Cash & cash equivalent $ 40 Millions Visit ME's Balance sheet
Source of ME's Sales Visit ME's Sales by Geography


Cumulative 23andme Holding Co's Quick Ratio

ME's Quick Ratio for the trailling 12 Months

ME Quick Ratio

 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth -3.55 % 12.1 % 10.63 % -1.84 % -17.13 %
Y / Y Cash & cash equivalent TTM Growth -67.92 % -59.78 % -50.63 % -45.66 % -42.7 %
Quick Ratio TTM 0.58 0.78 1.04 1.35 1.74
Total Ranking TTM # 795 # 3374 # 3017 # 3096 # 545
Seq. Current Liabilities TTM Growth -7.8 % -6.5 % 1.64 % 10.08 % 7.16 %
Seq. Cash & cash equivalent TTM Growth -31.42 % -30.09 % -21.58 % -14.66 % -14.02 %

Quick ratio ranking by company, industry and sector >> Back to ME Financial Strength Comparisons >> Go to Compare ME Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in ME's Current Liabilities to $111.38 millions, cumulative Quick Ratio to 0.58 below the ME average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 42 other companies have achieved higher Quick Ratio than 23andme Holding Co. While Quick Ratio overall ranking has improved so far to 795, from total ranking during the twelve months ending fourth quarter 2025 at 3374.

Explain Quick Ratio?
How much Cash & cash equivalents ME´s has?
What are ME´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 43
Healthcare Sector # 125
Within the Market # 795


trailing twelve months Quick Ratio Statistics
High Average Low
4.59 2.45 0.58
(Mar 31 2022)   (Jun 30 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2025 MRQ Cash & cash equivalentJun 30 2025 MRQ Current Liabilities
Theriva Biologics inc   0.98 $ 12.120  Millions$ 12.394  Millions
Evolus Inc   0.97 $ 61.738  Millions$ 63.750  Millions
Clene Inc   0.96 $ 7.285  Millions$ 7.574  Millions
Imunon Inc   0.96 $ 4.729  Millions$ 4.935  Millions
Moleculin Biotech Inc   0.96 $ 7.557  Millions$ 7.913  Millions
Aeon Biopharma inc   0.92 $ 8.439  Millions$ 9.129  Millions
Ani Pharmaceuticals Inc  0.92 $ 217.797  Millions$ 236.835  Millions
Nanobiotix S a   0.92 $ 59.080  Millions$ 64.408  Millions
Kamada Ltd   0.90 $ 65.985  Millions$ 73.057  Millions
Axsome Therapeutics Inc   0.89 $ 303.016  Millions$ 342.099  Millions
Ensysce Biosciences Inc   0.88 $ 2.212  Millions$ 2.513  Millions
Bausch Health Companies Inc   0.87 $ 1,727.000  Millions$ 1,980.000  Millions
Reviva Pharmaceuticals Holdings Inc   0.86 $ 10.364  Millions$ 12.077  Millions
Integrated Biopharma Inc  0.85 $ 3.615  Millions$ 4.248  Millions
Beyondspring Inc   0.84 $ 9.544  Millions$ 11.423  Millions
Legend Biotech Corporation  0.83 $ 266.586  Millions$ 321.814  Millions
Durect Corp  0.82 $ 6.502  Millions$ 7.893  Millions
Hyperion Defi inc   0.82 $ 8.420  Millions$ 10.311  Millions
Os Therapies Incorporated  0.81 $ 2.802  Millions$ 3.458  Millions
Incannex Healthcare Inc  0.81 $ 15.039  Millions$ 18.590  Millions
Fibrobiologics Inc   0.81 $ 8.845  Millions$ 10.964  Millions
Rein Therapeutics Inc   0.74 $ 5.722  Millions$ 7.694  Millions
Lifevantage Corp  0.74 $ 20.201  Millions$ 27.217  Millions
Assertio Holdings inc   0.74 $ 98.183  Millions$ 132.529  Millions
Grace Therapeutics Inc  0.73 $ 1.918  Millions$ 2.618  Millions
Jupiter Neurosciences Inc   0.73 $ 1.878  Millions$ 2.582  Millions
Indaptus Therapeutics Inc   0.73 $ 6.158  Millions$ 8.478  Millions
Azitra Inc   0.72 $ 1.046  Millions$ 1.452  Millions
Actuate Therapeutics Inc   0.71 $ 6.493  Millions$ 9.201  Millions
Cumberland Pharmaceuticals Inc   0.68 $ 16.087  Millions$ 23.586  Millions

Date modified: 2026-09-26T07:39:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.